Previous close | 198.05 |
Open | 199.85 |
Bid | 201.40 x 30000 |
Ask | 202.00 x 30000 |
Day's range | 195.75 - 199.80 |
52-week range | 126.90 - 219.00 |
Volume | |
Avg. volume | 34 |
Market cap | N/A |
Beta (5Y monthly) | N/A |
PE ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
Hologic's (HOLX) GYN Surgical Q2 performance was driven by strong results from MyoSure and Fluent Fluid Management.
Lantheus' (LNTH) robust revenues from the majority of its segments drive its first-quarter performance.
Bruker's (BRKR) BioSpin segment witnessed growth across biopharma, academic government and industrial research in the first quarter of 2024.